Cargando…

IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT

We report a 28-year-old Asian male patient, known for ITP and in partial remission for eighteen months, who presented to emergency department with ITP relapse (platelets count of 1 × 10^3 /uL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intr...

Descripción completa

Detalles Bibliográficos
Autor principal: Qasim, Hana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Editora Ltda. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572575/
http://dx.doi.org/10.1016/j.htct.2021.10.1046
_version_ 1784595241362259968
author Qasim, Hana
author_facet Qasim, Hana
author_sort Qasim, Hana
collection PubMed
description We report a 28-year-old Asian male patient, known for ITP and in partial remission for eighteen months, who presented to emergency department with ITP relapse (platelets count of 1 × 10^3 /uL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intravenous immunoglobulins and dexamethasone, we discuss as well the likely underlying pathophysiology and the suggested approach in patients known for ITP who are willing to receive mRNA COVID vaccines.
format Online
Article
Text
id pubmed-8572575
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Editora Ltda.
record_format MEDLINE/PubMed
spelling pubmed-85725752021-11-08 IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT Qasim, Hana Hematol Transfus Cell Ther PLATELET DISEASES We report a 28-year-old Asian male patient, known for ITP and in partial remission for eighteen months, who presented to emergency department with ITP relapse (platelets count of 1 × 10^3 /uL), four days after receiving the second dose of Pfizer SARS-CoV-2 vaccine, which required treatment with intravenous immunoglobulins and dexamethasone, we discuss as well the likely underlying pathophysiology and the suggested approach in patients known for ITP who are willing to receive mRNA COVID vaccines. Published by Elsevier Editora Ltda. 2021-11 2021-11-07 /pmc/articles/PMC8572575/ http://dx.doi.org/10.1016/j.htct.2021.10.1046 Text en Copyright © 2021 Published by Elsevier Editora Ltda. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle PLATELET DISEASES
Qasim, Hana
IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title_full IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title_fullStr IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title_full_unstemmed IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title_short IMMUNE THROMBOCYTOPENIA RELAPSE POST COVID-19 VACCINE IN YOUNG MALE PATIENT
title_sort immune thrombocytopenia relapse post covid-19 vaccine in young male patient
topic PLATELET DISEASES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572575/
http://dx.doi.org/10.1016/j.htct.2021.10.1046
work_keys_str_mv AT qasimhana immunethrombocytopeniarelapsepostcovid19vaccineinyoungmalepatient